This HTML5 document contains 191 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://dx.doi.org/10.1002/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q47591657
rdf:type
wikibase:Item
schema:description
tudományos cikk ডিসেম্বর ২০১৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ vedecký článok article scientific wissenschaftlicher Artikel scientific article published in December 2017 مقالة علمية نشرت في ديسمبر 2017 научни чланак teaduslik artikkel vetenskaplig artikel scienca artikolo 2017年學術文章 2017年学术文章 wetenschappelijk artikel articol științific 2017 nî lūn-bûn artikull shkencor научная статья videnskabelig artikel научни чланак บทความทางวิทยาศาสตร์ 2017年學術文章 scientific article published in December 2017 artigo científico 2017年学术文章 vědecký článek 2017年學術文章 מאמר מדעי 2017年学术文章 2017年学术文章 επιστημονικό άρθρο artículu científicu naučni članak article scientifique artykuł naukowy tieteellinen artikkeli vitskapeleg artikkel 2017年の論文 2017年學術文章 artikulong pang-agham 2017년 논문 bilimsel makale наукова стаття, опублікована в грудні 2017 artículo científico publicado en 2017 2017年學術文章 article científic artigo científico научна статия artikel ilmiah vitenskapelig artikkel 2017年学术文章 bài báo khoa học 2017年学术文章 мақолаи илмӣ სამეცნიერო სტატია articolo scientifico scientific article published in December 2017 artigo científico
p:P577
wds:Q47591657-69955C76-76C7-4496-81DA-DBA5EBA16391
wdt:P577
2017-12-01T00:00:00Z
p:P2860
wds:Q47591657-0377E6CB-302E-4967-8DFE-B654C15B67AB wds:Q47591657-056F4EB9-7AD2-40DD-A416-B6AFECBA9F31 wds:Q47591657-0B02DF89-26D4-43C5-843D-E5125EBBF019 wds:Q47591657-0C0DB0C2-94F7-4BD2-86F7-F3F2566AA9EF wds:Q47591657-2709FADE-8EA9-428D-8FC8-E724AF61CE1D wds:Q47591657-2A939A5B-9264-43AA-A905-042B7C3705CE wds:Q47591657-2C555D68-546E-45D6-B0FC-A7A27D20699D wds:Q47591657-40390E21-7BDB-4C07-B4B3-E6F2C2075FD8 wds:Q47591657-4045566A-2239-4CA1-A961-299F555986A4 wds:Q47591657-5D346D20-E6E6-48DD-8282-AD778A9BB6AB wds:Q47591657-5F3D59DC-CDF4-420D-A369-0D9D2D744B53 wds:Q47591657-DA51E483-8738-4334-A5B0-D2A9F0237A65 wds:Q47591657-DCC4D444-9420-4352-AB21-454A57C5C8C4 wds:Q47591657-EC867A68-E38D-4D5B-B25C-90CEF52213B1 wds:Q47591657-EDCD800D-8DB6-4EE2-A200-3D585780CB6C wds:Q47591657-EF867B94-2627-4D12-B999-23C0554BBBB1 wds:Q47591657-F82A0E87-A885-4BCD-8EA8-129AAE631EEA wds:Q47591657-FC62320E-9CF2-4E66-AD60-8F1AC6CCBDA3 wds:Q47591657-FCFB6ED1-EAC2-42FF-BABD-6FAA2A3D15DD wds:Q47591657-FD64B4F7-9A14-480C-A35E-35B677086D64 wds:Q47591657-FE3D5864-A95B-4FCF-8D45-17242CF7379E wds:Q47591657-600FF89A-E72B-47DD-AEE0-222B79BB4E9B wds:Q47591657-62D7E193-F9F1-4E3B-8D91-956054296AD0 wds:Q47591657-6744FEA6-F902-460A-A197-DBFEEBAF5B2E wds:Q47591657-6775D4C1-1650-452A-B8B8-71F452491484 wds:Q47591657-7382C79B-0555-4A0B-93A5-00427B8206A6 wds:Q47591657-7858D501-64EE-4714-9587-D0394A18DBFF wds:Q47591657-7DB2198C-8D7A-4A35-ABAA-007D9D94C017 wds:Q47591657-7F6357F0-BA5E-4BA5-8EA3-72933EDCC2B9 wds:Q47591657-8A73B9D5-959D-4EAA-B843-4CB0C792EF02 wds:Q47591657-90B14059-590A-4C9F-9F1C-0A40945A97E7 wds:Q47591657-9D218F65-E2DE-4918-8EF2-0D01F7F1B56B wds:Q47591657-9FFB7817-DFFA-420C-B37B-0851860EFC42 wds:Q47591657-A37427E1-82EC-41F5-AC1F-3B7446B102F7 wds:Q47591657-ADF9E32B-B3FF-45C8-8D8C-E6D7524F20D6 wds:Q47591657-B295C4BC-E982-46B9-A127-89D45067EEF5 wds:Q47591657-B67A4D58-AD9B-4DF5-BBD7-EEDCF7129726 wds:Q47591657-B737E885-8773-4AEB-848D-31015263DA0F wds:Q47591657-C2E35DCB-27BC-4C57-95B3-456F817E750C wds:Q47591657-C601B786-8503-40F2-95FA-D75DD8BF5FEC wds:Q47591657-C8E072EB-5B0F-4298-A51E-FF13B1A437F3 wds:Q47591657-CC96137D-CDA0-4C13-BFB7-E84846CB14AD
wdt:P2860
wd:Q33560604 wd:Q56879288 wd:Q57824012 wd:Q33567110 wd:Q43724280 wd:Q24186106 wd:Q39632069 wd:Q33908121 wd:Q39907084 wd:Q33792407 wd:Q38554066 wd:Q34328778 wd:Q39226007 wd:Q38396543 wd:Q37982351 wd:Q36059146 wd:Q38299133 wd:Q54164380 wd:Q34409802 wd:Q46949430 wd:Q38538817 wd:Q36968760 wd:Q43752807 wd:Q51562704 wd:Q39455773 wd:Q38105984 wd:Q38784389 wd:Q35709373 wd:Q36940162 wd:Q24202210 wd:Q39369921 wd:Q39702715 wd:Q35166613 wd:Q39465072 wd:Q35096421 wd:Q61831096 wd:Q38392739 wd:Q30978127 wd:Q36599205 wd:Q55059804 wd:Q34011187 wd:Q61646523
p:P2093
wds:Q47591657-1842C863-E9F8-42E6-9B0F-6478F6A9C136 wds:Q47591657-19020177-ED9E-4B3D-A92A-90E633705095 wds:Q47591657-0B770BEB-695F-4A37-995F-B8C66215F5A9 wds:Q47591657-BC7BC8BA-3161-4B1C-8826-9E23DBCEDF75 wds:Q47591657-D059847E-DD9B-40D9-8FDE-F1F38F196DFC wds:Q47591657-C50CCE1D-9C17-46A9-938B-5CBB0D521D3C wds:Q47591657-DB095EED-FBE4-4A0E-B1C6-E4D77966F876 wds:Q47591657-D110BE1C-5FD7-4606-9F06-5A06C9BE4215
wdt:P2093
Raynaud Study Investigators Ariane L Herrick Éric Hachulla Aline Frey Christopher P Denton Andreas Schwarting Franck-Olivier Le Brun Jean-Marie Frenoux
rdfs:label
Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.
skos:prefLabel
Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.
schema:name
Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.
p:P50
wds:Q47591657-BC1920B9-4634-43E1-AE72-E50EF8337E10
wdt:P50
wd:Q21260007
p:P1476
wds:Q47591657-CFEF7C64-874A-4736-AC35-FFE3EB03A750
wdt:P1476
Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.
p:P304
wds:Q47591657-B292F679-2383-4973-B1BE-057960292239
wdt:P304
2370-2379
p:P31
wds:Q47591657-201108CD-AFAA-4623-ABCC-368FDAE8E4FD
wdt:P31
wd:Q13442814
p:P921
wds:Q47591657-55A594CC-7240-40C3-B50B-0FB9D46CD7AD
wdt:P921
wd:Q269829
p:P698
wds:Q47591657-2E43BBE0-0B3B-4888-99A0-C5CD498BFE1F
wdtn:P698
n12:29193819
wdt:P698
29193819
p:P1433
wds:Q47591657-B00D6D4B-68F2-4316-BBF7-79F507618248
wdt:P1433
wd:Q4797636
p:P433
wds:Q47591657-14358880-361F-4554-9C1B-CC620FADA2FA
p:P478
wds:Q47591657-CE42A1E0-0CA3-4169-8626-DAFBD200FBE7
wdt:P433
12
wdt:P478
69
p:P356
wds:Q47591657-60B422F4-669F-4FC5-BAF0-B63A82BCA2B2
wdtn:P356
n11:ART.40242
wdt:P356
10.1002/ART.40242
p:P932
wds:Q47591657-9EFCEBD8-0C4E-4A0F-A97A-DCFFE72EC8FB
wdt:P932
6099416